PAIN TRIGGERS
Experiencing severe irritability when the stimulant medication wears off.
Extended-release medication does not last the advertised 8-10 hours.
Other· ADHD patientsPain 8.00/10WTP 7.0/10Market 8.0/10Validation 8.0Confidence 88%Oct 7, 2026
DoseDial: Smart Titration Tracker for ADHD Medication
ADHD patients lack a clear, data-driven framework to distinguish between normal temporary adjustment side effects and an incorrect dosage, leading to painful daily 'crashes', severe irritability, and prolonged trial-and-error periods.
analyticshealthcaremobile-appmonitoringnon-technical-usersreporting
1
STAGE 01 · PROBLEM
Is the problem real?
CANONICAL PROBLEM
ADHD patients undergoing medication titration struggle to identify their optimal dose, lacking clear heuristics to distinguish between temporary adjustment side effects and a dose that is simply too high.
FREQUENCY
Multiple repeated complaints in the post and comments.
INTENSITY
Users explicitly describe existing tools as bloated/overkill and mention workaround behavior.
EVIDENCE
How do you know if you’re on the proper dose (adderall)?
ADHD23
How do you know if you’re on the proper dose (adderall)?
ADHD23
How do you know if you’re on the proper dose (adderall)?
ADHD23
2
STAGE 02 · CUSTOMER
Who feels this pain?
TARGET USERS
ADHD patientsA D H D Patients In Titration
Patients undergoing trial-and-error to find their optimal stimulant dosage while managing severe side effects.
Context
Find the correct ADHD medication dosage that maximizes focus and symptom relief while minimizing adverse physical and emotional side effects.
Using smartwatches and at-home medical equipment to self-monitor vital signs and quantify side effects.
Crowdsourcing medical and dosing validation from online peer communities instead of waiting for a doctor's appointment.
Current Workarounds
Tracking vital signs with smartwatches to quantify side effects
Crowdsourcing medical validation from online peer communities like Reddit
Guessing if side effects are temporary adjustments or permanent signs of over-dosing
3
STAGE 03 · MARKET
Where's the gap?
EXISTING SOLUTION GAPS
Patients lack a clear, day-to-day framework to differentiate normal adjustment side effects from improper dosing.
Psychiatric titration relies heavily on slow trial-and-error, leaving patients to suffer through 'crashes' and side effects in the interim.
Medical guidance on expected duration (e.g., XR lasting 8-10 hours) often does not match real-world patient metabolism, leading to confusing premature dose increases.
OPPORTUNITY & VALUE
Why Now
Complaints about severe irritability when medication wears off are repeated across original posts and commenters.
Value Proposition
Purpose-built for the 4-8 week ADHD titration window with specific focus on predicting and tracking the 'crash', unlike generic mood or habit trackers.
Product Direction
A mobile app that combines smartwatch vital data (heart rate/sleep) with a low-friction daily check-in to track the duration of focus vs. the onset of irritability 'crashes', generating a clear report for the prescribing doctor.
4
STAGE 04 · BUSINESS
How does it make money?
MONETIZATION
$9/moActive during the 3-6 month titration phase
Model
B2C Subscription
WILLINGNESS TO PAY
Patients already spend heavily on smartwatches to track vitals and endure severe daily emotional crashes. Shortening this painful phase provides high, immediate ROI.
5
STAGE 05 · EXECUTION
How do you ship it?
MVP PLAN
“Find your perfect ADHD medication dose without the guesswork.”
A mobile app that combines smartwatch vital data (heart rate/sleep) with a low-friction daily check-in to track the duration of focus vs. the onset of irritability 'crashes', generating a clear report for the prescribing doctor.
Core Features
One-tap daily logging for medication intake, focus peak, and irritability crash
Apple Watch/Garmin integration for baseline heart rate monitoring
Exportable 14-day titration report for psychiatrists
Weekly Roadmap
1
W1-W2
Core tracking loop for medication timing, focus, and crash logging.
- •Build iOS app scaffold
- •Implement one-tap medication logging
- •Implement simple crash/irritability logger
2
W3-W4
Integration with Apple Health to pull vital signs.
- •Implement HealthKit integration for heart rate and sleep
- •Build daily timeline view correlating vitals with logged moods
3
W5
Doctor export functionality and beta onboarding.
- •Generate PDF titration report for doctor visits
- •Onboard 20 beta users from r/ADHD
4
W6
Public launch with subscription paywall.
- •Implement Stripe/RevenueCat billing
- •Launch on Product Hunt and ADHD subreddits
- •Publish launch case study on finding the optimal dose
Launch Strategy
Direct-to-consumer via TikTok ADHD creators and Reddit communities (r/ADHD), plus organic SEO for 'Adderall crash tracking'.
RISKS & ASSUMPTIONS
Top Risks
Medical Regulation (FDA)
Risk of being classified as a medical device if the app algorithms suggest dosage changes.
ADHD User Retention
Target users inherently struggle with executive function and may abandon daily tracking after a few days.
Built-in Churn
The product is highly successful when it helps a user find their dose, meaning they immediately stop needing the app.
6
STAGE 06 · DECISION
Should you build it?
NEED A CLEARER CALL?
Run an Investment Memo to get a structured Go / No-Go verdict, competitor landscape, unit economics, and a 90-day validation roadmap for this opportunity.
Generate an investment memoWhat this score means
This opportunity scores well above the median for ideas surfaced by MonetScope, with a validation sub-score of 8/10 against 3 independently sourced evidence signals. A "strong" rating in this band typically means the pain signal is consistent and recurring across multiple discussions, but one of the three pillars (severity, willingness to pay, or competitor weakness) is somewhat softer than top-tier opportunities. Founders evaluating this should focus customer discovery on the softest pillar first — confirming the gap before committing engineering time to a build.
Why this matters for Other founders
It sits at the intersection of "analytics", "healthcare", "mobile-app", which makes it relevant to a specific subset of founders rather than a generic horizontal opportunity. Opportunities in this category typically reward founders who can describe the pain in the user's own language — both because that's the basis of effective marketing, and because it's the strongest signal that the founder has done the upfront listening. The MonetScope pipeline surfaces this category alongside other other signals, which is why it appears here rather than in a generic "trending ideas" feed.
Scores are derived from real forum discussions across Reddit, Hacker News and X, weighted by evidence volume and signal quality. How scoring works
Frequently asked questions
Is "DoseDial: Smart Titration Tracker for ADHD Medication" a real validated startup idea or just an AI-generated suggestion?
MonetScope does not generate ideas from a language model's imagination. Every opportunity on this site is anchored to specific source posts and comments from real public discussions — typically on Reddit, Hacker News, or X — where actual users describe the pain in their own words. The AI's role is structuring, scoring, and grouping those signals into a navigable opportunity, not inventing the problem.
How recent is the underlying data for analytics?
MonetScope's spider pipeline runs continuously and surfaces opportunities as new evidence accumulates. The "Updated" date in the header reflects the most recent re-scoring of this specific opportunity. Most other opportunities visible in the public catalog draw from discussions in the last 30-60 days; older signals are de-prioritized because user pain shifts faster than most founders assume.
What's the difference between "overall score" and "validation score"?
Overall score is a composite across six dimensions — pain, urgency, willingness to pay, market size, defensibility, and execution ease — designed to give a single number for triage. Validation score is narrower: it asks "how cleanly does the same signal repeat across independent sources?" An opportunity can score high on overall but lower on validation when one or two large discussions dominate the evidence; conversely, validation can be high on a smaller-overall idea where the signal is consistent but the addressable market is modest.